By performing a large-scale observational analysis of Medicare and commercial claims, we were able to see how the UroLift System and other BPH therapies perform in the real-world post-treatment,” said Kevin Hardage, President of the Teleflex Interventional Urology business unit.
“Surgical retreatment is an important factor for urologists and their patients to consider when evaluating BPH therapies. Rezum was associated with a higher risk of surgical retreatment: 36% higher Rezum vs PUL (p=0.03), 40% higher Rezum vs TURP (p=0.01), 43% higher Rezum vs GreenLight (p=0.009). When assessing risk at 365 days via hazard modeling, there was a similar risk of surgical retreatment associated with GreenLight, TURP, and UroLift PUL. The rate of surgical retreatment for Rezum (7.2%) was higher compared to UroLift PUL (p=0.04). Surgical retreatment rates at the 365-day mark were similar between GreenLight (5.2%), TURP (5.3%), and PUL (5.4%). Adjusting for available population variables using hazard modeling, UroLift PUL was associated with a lower risk of undergoing a return procedure compared to GreenLight, Rezum, and TURP: 24% higher TURP vs PUL (p<0.0001), 35% higher GreenLight vs PUL (p<0.0001), 41% higher Rezum vs PUL (p<0.0001).2. Results from the analysis showed : 1.Post-treatment return procedure rates at the 365-day mark were lowest (17%) with UroLift PUL patients and highest (23%) among Rezum patients (UroLift PUL vs Rezum: p<0.0001). The analysis utilized a Cox proportional hazard model to account and adjust for variables which may have differed between treatment populations, such as age, cost of index procedure, comorbidities, adverse events, and site of service. The research defines differences between return procedures (post-operative procedure performed during a return visit to an outpatient setting identified by a CPT or ICD 9/10 code), and surgical retreatment occurring after the original index. The database included 5,228 UroLift System prostatic urethral lift (PUL) patients 19,507 transurethral resection of the prostate (TURP) patients 10,173 GreenLight patients and 935 Rezum patients.
Medicare and commercial claims from IBM Watson among men with a BPH diagnosis who received therapy for the condition in an outpatient setting from 2015 through 2019. The study analyzed a representative sample of U.S. “This study revealed real-world surgical retreatment rates that are comparable among the UroLift System, TURP and GreenLight while highest for Rezum.” Until now, comprehensive healthcare utilization data that includes surgical retreatment rates have been missing from the urologist toolbox when discussing these important factors surrounding treatment options with their BPH patients,” said Dr. “It is important for urologists to have access to well-designed, large-scale, real-world comparative data for surgical and minimally invasive BPH treatments. Medicare and Commercial Claims,” which was sponsored by Teleflex, was presented Sunday, September 12 by Steven Kaplan+, M.D., of Mount Sinai, New York City, at the virtual American Urological Association (AUA) 2021 Annual Meeting. The study “UroLift PUL Compared to Rezum, TURP and GreenLight PVP: Results From an Analysis of U.S. The data also show that the risk of surgical retreatment is similar between UroLift PUL, TURP and GreenLight PVP while highest following Rezum Water Vapor Therapy. Teleflex Incorporated announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift System among the analyzed benign prostatic hyperplasia (BPH) treatment options.
0 kommentar(er)
